期刊文献+

Association between Uric Acid and Metabolic Syndrome in Homozygous Sickle Cell Patients

Association between Uric Acid and Metabolic Syndrome in Homozygous Sickle Cell Patients
下载PDF
导出
摘要 <span style="font-family:Verdana;">The objective of this study was to assess the association between uric acid and </span><span style="font-family:Verdana;">the metabolic</span><span style="font-family:Verdana;"> syndrome and its components in homozygous sickle cell patients. This is a prospective case/control study of sickle cell SS patients</span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">.</span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;"> Each patient was matched to a control of the same sex and age ± 2 years. In our </span><span style="font-family:Verdana;">framework</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">,</span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;"> we used the criteria for defining metabolic syndrome according to International Diabetes Federation (IDF) 2009. </span><span style="font-family:Verdana;">Assay</span><span style="font-family:Verdana;"> of all biological parameters was performed with the ARCHITECT ci4100, Abbot (Chicago, Illinois, USA). Data were collected with Excel 2016 software and statistical analysis was done using XLSTAT 2019 software</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">. </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">Student’s</span></span></span><span><span><span style="font-family:;" "=""> <span style="font-family:Verdana;">T test</span><span style="font-family:Verdana;"> was used to compare means and a </span><span style="font-family:Verdana;">p</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">-</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">value</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> less than 0.05 was considered significant.</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">The study population consisted of 100 homozygous sickle cell patients with an average age of 26 years with a sex ratio of 0.58. The prevalence of metabolic syndrome in our population according to the IDF 2009 was 2%. In our study 28% of patients presented with hyperuricemia. Uricaemia was significantly elevated in patients with components of the metabolic syndrome, in particular in 33% of patients with a large waist circumference, in 25% of hypertensive patients, in 50% of patients with hypertriglyceridemia </span><span style="font-family:Verdana;">and</span> <span style="font-family:Verdana;">in</span><span style="font-family:Verdana;"> 60% of patients with hypertriglyceridemia and low HDL-cholesterol levels. Significant correlations were found between uricemia and certain components of the metabolic syndrome, in particular the level of triglycerides (r = 0.31, p = 0.002), blood sugar (r = 0.16;</span><span style="font-family:Verdana;">p = 0.012), around size (r = 0.071;p </span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">≤</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">0.05), HDL-Cholesterol (r = </span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;"><span style="white-space:nowrap;">﹣</span></span><span style="font-family:Verdana;">0.01;p = 0.018), PAS (r = 0.076;p = 0.035) and PAD (r = <span style="white-space:nowrap;">﹣</span></span><span style="font-family:Verdana;">0.18;p = 0.0015).</span></span></span></span> <span style="font-family:Verdana;">The objective of this study was to assess the association between uric acid and </span><span style="font-family:Verdana;">the metabolic</span><span style="font-family:Verdana;"> syndrome and its components in homozygous sickle cell patients. This is a prospective case/control study of sickle cell SS patients</span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">.</span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;"> Each patient was matched to a control of the same sex and age ± 2 years. In our </span><span style="font-family:Verdana;">framework</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">,</span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;"> we used the criteria for defining metabolic syndrome according to International Diabetes Federation (IDF) 2009. </span><span style="font-family:Verdana;">Assay</span><span style="font-family:Verdana;"> of all biological parameters was performed with the ARCHITECT ci4100, Abbot (Chicago, Illinois, USA). Data were collected with Excel 2016 software and statistical analysis was done using XLSTAT 2019 software</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">. </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">Student’s</span></span></span><span><span><span style="font-family:;" "=""> <span style="font-family:Verdana;">T test</span><span style="font-family:Verdana;"> was used to compare means and a </span><span style="font-family:Verdana;">p</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">-</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">value</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> less than 0.05 was considered significant.</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">The study population consisted of 100 homozygous sickle cell patients with an average age of 26 years with a sex ratio of 0.58. The prevalence of metabolic syndrome in our population according to the IDF 2009 was 2%. In our study 28% of patients presented with hyperuricemia. Uricaemia was significantly elevated in patients with components of the metabolic syndrome, in particular in 33% of patients with a large waist circumference, in 25% of hypertensive patients, in 50% of patients with hypertriglyceridemia </span><span style="font-family:Verdana;">and</span> <span style="font-family:Verdana;">in</span><span style="font-family:Verdana;"> 60% of patients with hypertriglyceridemia and low HDL-cholesterol levels. Significant correlations were found between uricemia and certain components of the metabolic syndrome, in particular the level of triglycerides (r = 0.31, p = 0.002), blood sugar (r = 0.16;</span><span style="font-family:Verdana;">p = 0.012), around size (r = 0.071;p </span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">≤</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">0.05), HDL-Cholesterol (r = </span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;"><span style="white-space:nowrap;">﹣</span></span><span style="font-family:Verdana;">0.01;p = 0.018), PAS (r = 0.076;p = 0.035) and PAD (r = <span style="white-space:nowrap;">﹣</span></span><span style="font-family:Verdana;">0.18;p = 0.0015).</span></span></span></span>
作者 Kandji Pape Matar Djite Moustapha Barry Nene Oumou Kesso Sagne Rene Ngor Thioune Ndeye Mareme Mbacke Ndoumbé Mame Ndour El Hadji Malick Gueye-Tall Fatou Lopez-Sall Philomene Cisse Aynina Diop Pape Amadou Gueye Papa Madieye Kandji Pape Matar;Djite Moustapha;Barry Nene Oumou Kesso;Sagne Rene Ngor;Thioune Ndeye Mareme;Mbacke Ndoumbé Mame;Ndour El Hadji Malick;Gueye-Tall Fatou;Lopez-Sall Philomene;Cisse Aynina;Diop Pape Amadou;Gueye Papa Madieye(Laboratory of Biochemistry-Hematology, National University Hospital of Fann, Dakar, Senegal;Laboratory of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy, Cheikh Anta Diop University, Dakar, Senegal)
出处 《Advances in Biological Chemistry》 2021年第3期142-148,共7页 生物化学进展(英文)
关键词 Sickle Cell Disease Metabolic Syndrome Uric Acid IDF 2009 Sickle Cell Disease Metabolic Syndrome Uric Acid IDF 2009
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部